This book helps readers integrate in silico, in
vitro, and in vivo ADMET (absorption,
distribution, metabolism, elimination and toxicity) and PK
(pharmacokinetics) data with routine testing applications so that
pharmaceutical scientists can diagnose ADMET problems and present
appropriate recommendations to move drug discovery programs
forward.
The book introduces the current clinical practice for drug
discovery and development along with the impact on early risk
assessment; consolidates the tools and models to intelligently
integrate existing in silico, in
vitro and in vivo ADMET data; and
demonstrates successful cases and lessons learned from real drug
discovery and development. In short, it is a book aimed to provide
a practical road map for drug discovery and development scientists
to generate efficacious and safe drugs for unmet medical needs.
关于作者
Jianling Wang is the Cambridge Head of Discovery
ADME at Novartis Institutes for Bio Medical Research. He has
published over 40 journal papers, reviews, and book chapters and
lectured at over 30 scientific conferences and courses.
Laszlo Urban is the Executive Director for Preclinical
Safety Profiling at Novartis Institutes for Bio Medical Research. He
has over 10 years of experience in academia and 20 years in the
pharmaceutical industry. Among Dr. Urban’s publications are
over 120 peer-reviewed scientific papers, 3 books
including Hit and Lead Profiling: Identification and
Optimization of Drug-like Molecules (Wiley, 2009).
来自同一作者的更多电子书 / 编辑
28,085 此类电子书
